Linlang Guo

Linlang Guo

Auto-generated profile, based on publicly available information

Linlang Guo

Department of Pathology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong 510282, PR China

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2025 in Research
Verified
Journal Article
Open access
JCJie Chen
Jie Chen
XLXiaodie Li
Xiaodie Li
QCQian Chen
Qian Chen
XZXuyang Zhou
Xuyang Zhou
JZJialin Zeng
Jialin Zeng
CZChao Zhang
Chao Zhang
Chemoresistance is a primary cause of cancer treatment failure, due to the lack of specific regulatory strategies arising from unclear mechanisms. Here, we uncover the pivotal role of the PRMT1/SOX2 axis in regulating cancer stemness, a key factor contributing to cancer chemoresistance. In light of this, we construct a DNA nanomachine (DNM) to overcome chemoresistance by reversing cancer stemness. This DNM is constructed using a programmable DNA origami framework, incorporating CD44-targeting aptamers and glutathione (GSH)-responsive stemness inhibitors (DCLX069) as functional components. The DNM exhibits a specific affinity toward CD44-overexpressing tumor cells, enabling the effective delivery of the loaded cisplatin (CDDP) to the tumor cells. Upon entering the tumor cells, DCLX069 is rapidly released from the DNM due to high intracellular GSH levels, leading to swift regulation of the PRMT1/SOX2 axis. In contrast, CDDP exhibits a gradual enzymatic release profile. This temporally programmed release enables the reversal of cancer stemness before chemotherapy initiation, resulting in a substantial improvement in CDDP chemosensitivity and a significant increase in the median survival of tumor-bearing mice from 27 to over 56 d with DNM assistance. This study highlights the promising potential of this DNA nanotechnology-empowered therapy in addressing chemoresistance in malignant tumors.

4 December 2025 in SLAS Technology
Verified
Journal Article
Open access
ZPZhengqi Peng
Zhengqi Peng
QCQian Chen
Qian Chen
PNPengkhun Nov
Pengkhun Nov
MSMohsin Farid Sulehri
Mohsin Farid Sulehri
YLYujing Liu
Yujing Liu
MWMengchuan Wang
Mengchuan Wang
Cold tumors, characterized by low cytotoxic T cell infiltration, limit immunotherapy efficacy. Current strategies often depend on tumor-specific antigens or non-specific immune activation, restricting translational potential. Here, we present a peptide-based platform that leverages intratumoral expression of influenza-derived peptides to redirect virus-specific CD8⁺ T cells and remodel the tumor immune microenvironment in an antigen-independent manner. In murine 4T1 and CT26 tumor models, the immunodominant influenza A virus peptide NP147-155 was delivered via intratumoral peptide injection or stable lentiviral expression. Immune remodeling was assessed using flow cytometry, cytokine profiling, and transcriptomic profiling. Differential gene expression and pathway analyses identified mechanisms underlying cold-to-hot TME conversion. Intratumoral NP147-155 expression robustly activated virus-specific CD8⁺ T cells and enhanced IFN-γ secretion. Transcriptomic profiling revealed upregulation of genes associated with cytotoxicity, chemokine signaling, antigen presentation, and the NKG2D-NKG2DL pathway, consistent with increased T cell infiltration and conversion of cold tumors into hot tumors. Tumor growth was significantly suppressed, and durable anti-tumor immunity was established, including in MHC class I-deficient tumors. This study demonstrates a peptide-based platform to remodel cold tumor immune microenvironments. Integration of transcriptomic profiling provides mechanistic insights and establishes a robust workflow for evaluating immunomodulatory technologies. This tumor-agnostic approach may enhance anti-tumor immunity and improve immunotherapy efficacy in cold tumors.